Pacific Biosciences of California Inc (NASDAQ: PACB) kicked off on Friday, down -6.37% from the previous trading day, before settling in for the closing price of $1.57. Over the past 52 weeks, PACB has traded in a range of $1.25-$14.55.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 24.48%. While this was happening, its average annual earnings per share was recorded 23.50%. With a float of $264.29 million, this company’s outstanding shares have now reached $267.74 million.
Considering the fact that the conglomerate employs 796 people, you should pay attention to its efficiency factor.
Pacific Biosciences of California Inc (PACB) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Pacific Biosciences of California Inc is 2.96%, while institutional ownership is 92.33%. The most recent insider transaction that took place on May 20 ’24, was worth 10,708. In this transaction an insider of this company sold 5,275 shares at a rate of $2.03, taking the stock ownership to the 211,941 shares. Before that another transaction happened on Mar 06 ’24, when Company’s Director bought 40,000 for $4.40, making the entire transaction worth $176,160. This insider now owns 40,000 shares in total.
Pacific Biosciences of California Inc (PACB) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.28 earnings per share (EPS), higher than consensus estimate (set at -0.32) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to -9.76% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Take a look at Pacific Biosciences of California Inc’s (PACB) current performance indicators. Last quarter, stock had a quick ratio of 8.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.14, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.73 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Compared to the last year’s volume of 9.75 million, its volume of 7.08 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 2.52%. Additionally, its Average True Range was 0.19.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 3.58%, which indicates a significant increase from 1.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.14% in the past 14 days, which was lower than the 141.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8554, while its 200-day Moving Average is $5.8376. Nevertheless, the first resistance level for the watch stands at $1.5667 in the near term. At $1.6633, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7167. If the price goes on to break the first support level at $1.4167, it is likely to go to the next support level at $1.3633. Should the price break the second support level, the third support level stands at $1.2667.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
The company with the Market Capitalisation of 400.37 million has total of 272,356K Shares Outstanding. Its annual sales at the moment are 200,520 K in contrast with the sum of -306,740 K annual income. Company’s last quarter sales were recorded 38,810 K and last quarter income was -78,180 K.
